( CSE: TRIP) ( OTCMKTS: TRUFF) have entered into a definitive scheme implementation deed to combine businesses and create The HighBrid Lab, a global psychedelics and cannabinoid company. ( OTCMKTS: COPHF) and Red Light Holland Corp. Creso Pharma and Red Light Holland Merge to Introduce The HighBrid Lab (TM), a Leading Global Psychedelics x Cannabis CompanyĬreso Pharma Ltd. Tier 1 is the TSXV’s premier tier and is reserved for the TSXV’s most advanced issuers with the most significant financial resources.Ĥ. The TSXV classifies listed issuers into different tiers based on standards including historical financial performance, stage of development and financial resources.
(emphasis ours) Payton Nyquvest, President, CEO and Chair, Numinus Going forward, we expect to achieve near-term catalysts across our business including clinic acquisitions, new intellectual property, MDMA and psilocybin compassionate access trials, in-clinic ketamine-assisted therapy and further up-listings in the US and Canada. This up-listing is another indication that Numinus has effectively advanced its healthcare strategy, met its business objectives and built a rapidly scalable growth platform to lead the emerging sector of psychedelic-assisted psychotherapy. By qualifying for up-listing to the TSXV’s top tier under the Life Sciences industry segment, Numinus will benefit from improved service standards, reduced compliance obligations and increased access to institutional investors. Numinus Wellness Inc. ( CVE:NUMI ) has received approval to graduate to Tier 1 Issuer status on the TSX Venture Exchange, effective June 18, 2021. Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange
Aside from presenting a synopsis of events, we provide market commentary to summarize the week that was for publicly-listed companies.ĥ. Welcome to TDR’s review of the Top 5 Psychedelic developments for the week of June 14.
0 kommentar(er)
